AstraZeneca PLCAZN:LSE

3,959.5
37.00 / 0.93 %
2.50m
12.94 %
0.6268
Close in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Apr 28 2016 17:01 BST.

About the company

17.00bn1.94bn199261.50k
Revenue in GBP (TTM)Net income in GBPIncorporatedEmployees
IndustryPharmaceuticals & BiotechnologyLocation
AstraZeneca PLC
- Legal Department, 2 Kingdom Street
LONDONW2 6BD
United Kingdom
GBR
Phone+44 20 7304 5000Fax+44 20 7604 8151Websitehttp://www.astrazeneca.com/
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).

Mergers & acquisitions

Acquired company
Deal status
DateAZN:LSE since
announced
Transaction
value
Takeda Pharmaceutical Co Ltd-Respiratory BusinessAnnounced16 Dec 2015+9.83 %575.00m
Acerta Pharma BVDeal completed14 Dec 2015+8.56 %4.00bn
ZS Pharma IncDeal completed06 Nov 2015+6.77 %2.69bn
Data delayed at least 15 minutes, as of Apr 28 2016 17:01 BST.

Peer analysis

Company Revenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings
(TTM)
Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excluding
extraordinary items (TTM)
EPS (including
extraordinary items) (TTM)
Revenue per
share (TTM)
Book value per
share (MRQ)
Asset turnover
(TTM)
Inventory turnover
(TTM)
Receivables turnover
(TTM)
Revenues per
employee (TTM)
Return on
average
assets
(TTM)
Return on
average
assets
(5 yr average)
Return on
investment
(TTM)
Return on
investment
(5 yr average)
Gross margin (TTM)Gross margin (5 yr average)Net profit margin (TTM)Net Profit margin (5 Yr Average)Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio (5 yr average)Revenue
(Year-over-year change%)
Revenue
(5 yr growth rate)
Net income
(Year-over-year change%)
Net income
(5 Yr growth rate)
Capital
expenditure
(5 Yr growth rate)
Dividend
(5 yr growth rate)
Actelion Ltd
1.50bn403.97m12.68bn2.50k30.4311.5127.428.465.165.1619.0713.640.89982.364.78--24.0512.8630.8917.0291.4689.3326.7318.802.3236.990.0036.584.451.18-7.06257.16-20.366113.40
Shire PLC
4.41bn920.00m24.83bn5.55k26.983.7218.265.621.551.517.4411.250.42441.625.74795,5538.8616.5111.3921.9285.1285.5020.8829.440.437155.640.13867.776.5513.08-59.257317.86-19.016915.17
AstraZeneca plc
17.00bn1.94bn50.68bn61.50k26.093.9813.392.981.541.5413.4410.060.41622.193.57276,3484.768.196.5411.4581.8480.7011.4416.480.93244.590.448578.91-6.9273-5.7764129.12-18.90165.031.89
GlaxoSmithKline plc
23.92bn8.42bn72.50bn101.19k8.5314.177.063.031.751.754.931.050.50851.804.68236,41217.7912.6326.6019.4066.3869.9535.0021.150.88486.600.65275.343.99-3.3673205.5938.813.064.24
Sanofi SA
27.10bn3.43bn78.37bn115.63k23.031.7315.112.893.343.2526.4944.590.34911.674.80301,4854.544.565.355.3068.6868.4013.0113.161.0931.520.221478.898.940.48023.23-4.201810.773.23
Novo Nordisk A/S
11.26bn3.64bn76.22bn40.64k26.8420.0719.316.7713.5213.5241.8718.081.281.347.572,655,81541.2935.2973.9455.7485.0083.2432.3029.451.047.900.022346.7521.5312.1731.6419.3410.4526.19
Data as of Apr 28 2016. Currency figures normalised to AstraZeneca PLC's reporting currency: .
Data delayed at least 20 minutes, as of Apr 28 2016 22:10 BST.

Institutional shareholders

HolderShares% Held
BlackRock Investment Management (UK) Ltd.
as of 31 Jan 2016
53.17m4.21%
Wellington Management Co. LLP
as of 01 Mar 2016
37.13m2.94%
Legal & General Investment Management Ltd.
as of 01 Mar 2016
36.68m2.90%
The Vanguard Group, Inc.
as of 01 Mar 2016
29.87m2.36%
Invesco Asset Management Ltd.
as of 01 Mar 2016
24.24m1.92%
Norges Bank Investment Management
as of 01 Mar 2016
23.61m1.87%
Woodford Investment Management LLP
as of 01 Mar 2016
22.27m1.76%
Threadneedle Asset Management Ltd.
as of 01 Mar 2016
19.22m1.52%
State Street Global Advisors Ltd.
as of 01 Mar 2016
17.06m1.35%
Capital Research & Management Co. (World Investors)
as of 31 Jan 2016
17.00m1.35%
22.17%
Per cent of shares
held by top holders
Data from 31 Dec 2015 - 21 Apr 2016Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.